Vulnerable Plaque Imaging

Muller, 1989, Circadian variation and triggers of onset of acute cardiovascular disease, Circulation, 79, 733, 10.1161/01.CIR.79.4.733

Muller, 1994, Triggers, acute risk factors and vulnerable plaques: The lexicon of a new frontier, J Am Coll Cardiol, 23, 809, 10.1016/0735-1097(94)90772-2

Davies, 1985, Plaque fissuring–The cause of acute myocardial infarction, sudden ischaemic death, and crescendo angina, Br Heart J, 53, 363, 10.1136/hrt.53.4.363

Virmani, 2000, Lessons from sudden coronary death: A comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler Thromb Vasc Biol, 20, 1262, 10.1161/01.ATV.20.5.1262

Naghavi, 2003, From vulnerable plaque to vulnerable patient: A call for new definitions and risk assessment strategies: Part I, Circulation, 108, 1664, 10.1161/01.CIR.0000087480.94275.97

Nakahara, 2017, Coronary artery calcification: From mechanism to molecular imaging, JACC Cardiovasc Imaging, 10, 582, 10.1016/j.jcmg.2017.03.005

Prati, 2020, Relationship between coronary plaque morphology of the left anterior descending artery and 12 months clinical outcome: The CLIMA study, Eur Heart J, 41, 383, 10.1093/eurheartj/ehz520

Kedhi, 2021, Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: The COMBINE OCT-FFR trial, Eur Heart J, 42, 4671, 10.1093/eurheartj/ehab433

Erlinge, 2021, Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): A prospective natural history study, Lancet, 397, 985, 10.1016/S0140-6736(21)00249-X

Uchida, 2017, Recent advances in fluorescent angioscopy for molecular imaging of human atherosclerotic coronary plaque, J Atheroscler Thromb, 24, 539, 10.5551/jat.40352

Narula, 2009, Napkin-ring necrotic cores: Defining circumferential extent of necrotic cores in unstable plaques, JACC Cardiovasc Imaging, 2, 1436, 10.1016/j.jcmg.2009.10.004

Ferencik, 2018, Use of high-risk coronary atherosclerotic plaque detection for risk stratification of patients with stable chest pain: A secondary analysis of the PROMISE randomized clinical trial, JAMA Cardiol, 3, 144, 10.1001/jamacardio.2017.4973

Károlyi, 2013, Classification of coronary atherosclerotic plaques ex vivo with T1, T2, and ultrashort echo time CMR, JACC Cardiovasc Imaging, 6, 466, 10.1016/j.jcmg.2012.09.015

Touzé, 2007, Reproducibility of high-resolution MRI for the identification and the quantification of carotid atherosclerotic plaque components: Consequences for prognosis studies and therapeutic trials, Stroke, 38, 1812, 10.1161/STROKEAHA.106.479139

Trelles, 2013, CTA for screening of complicated atherosclerotic carotid plaque–American Heart Association type VI lesions as defined by MRI, AJNR Am J Neuroradiol, 34, 2331, 10.3174/ajnr.A3607

Waki, 2003, Ultrasonic tissue characterization of the atherosclerotic carotid artery: histological correlates or carotid integrated backscatter, Circ J, 67, 1013, 10.1253/circj.67.1013

Nakahara, 2018, Molecular imaging of vulnerable plaque, Semin Nucl Med, 48, 291, 10.1053/j.semnuclmed.2018.02.004

Rhoads, 2018, How oxidized low-density lipoprotein activates inflammatory responses, Crit Rev Immunol, 38, 333, 10.1615/CritRevImmunol.2018026483

Hartung, 2007, Radiolabeled monocyte chemotactic Protein 1 for the detection of inflammation in experimental atherosclerosis, J Nucl Med, 48, 1816, 10.2967/jnumed.107.043463

Jaipersad, 2014, The role of monocytes in angiogenesis and atherosclerosis, J Am Coll Cardiol, 63, 1, 10.1016/j.jacc.2013.09.019

Kolodgie, 2003, Intraplaque hemorrhage and progression of coronary atheroma, N Engl J Med, 349, 2316, 10.1056/NEJMoa035655

Nagase, 1999, Matrix metalloproteinases, J Biol Chem, 274, 21491, 10.1074/jbc.274.31.21491

Hutcheson, 2016, Genesis and growth of extracellular-vesicle-derived microcalcification in atherosclerotic plaques, Nat Mater, 15, 335, 10.1038/nmat4519

Kelly-Arnold, 2013, Revised microcalcification hypothesis for fibrous cap rupture in human coronary arteries, Proc Natl Acad Sci U S A, 110, 10741, 10.1073/pnas.1308814110

Libby, 2019, Reassessing the mechanisms of acute coronary syndromes, Circ Res, 124, 150, 10.1161/CIRCRESAHA.118.311098

Partida, 2018, Plaque erosion: A new in vivo diagnosis and a potential major shift in the management of patients with acute coronary syndromes, Eur Heart J, 39, 2070, 10.1093/eurheartj/ehx786

Rudd, 2002, Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography, Circulation, 105, 2708, 10.1161/01.CIR.0000020548.60110.76

Rudd, 2010, Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: Ready for prime time?, J Am Coll Cardiol, 55, 2527, 10.1016/j.jacc.2009.12.061

Laitinen, 2010, Uptake of 11C-choline in mouse atherosclerotic plaques, J Nucl Med, 51, 798, 10.2967/jnumed.109.071704

Matter, 2006, 18F-choline images murine atherosclerotic plaques ex vivo, Arterioscler Thromb Vasc Biol, 26, 584, 10.1161/01.ATV.0000200106.34016.18

Cuhlmann, 2014, In vivo mapping of vascular inflammation using the translocator protein tracer 18F-FEDAA1106, Mol Imaging, 13, 1, 10.2310/7290.2014.00014

Hellberg, 2018, Positron Emission Tomography imaging of macrophages in atherosclerosis with (18)F-GE-180, a radiotracer for translocator protein (TSPO), Contrast Media Mol Imaging, 2018, 10.1155/2018/9186902

Gaemperli, 2012, Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography, Eur Heart J, 33, 1902, 10.1093/eurheartj/ehr367

Krantic, 2000, Peptides as regulators of the immune system: Emphasis on somatostatin, Peptides, 21, 1941, 10.1016/S0196-9781(00)00347-8

Froidevaux, 2002, Neuroendocrine tumor targeting: Study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model, Int J Cancer, 98, 930, 10.1002/ijc.10295

Rominger, 2010, In vivo imaging of macrophage activity in the coronary arteries using 68Ga-DOTATATE PET/CT: Correlation with coronary calcium burden and risk factors, J Nucl Med, 51, 193, 10.2967/jnumed.109.070672

Wan, 2017, PET/CT imaging of unstable carotid plaque with (68)Ga-labeled somatostatin receptor ligand, J Nucl Med, 58, 774, 10.2967/jnumed.116.181438

Tahara, 2014, 2-deoxy-2-[18F]fluoro-D-mannose positron emission tomography imaging in atherosclerosis, Nat Med, 20, 215, 10.1038/nm.3437

Zernecke, 2014, Chemokines in atherosclerosis: Proceedings resumed, Arterioscler Thromb Vasc Biol, 34, 742, 10.1161/ATVBAHA.113.301655

Zernecke, 2010, Chemokines in the vascular inflammatory response of atherosclerosis, Cardiovasc Res, 86, 192, 10.1093/cvr/cvp391

Ohtsuki, 2001, Detection of monocyte chemoattractant protein-1 receptor expression in experimental atherosclerotic lesions: An autoradiographic study, Circulation, 104, 203, 10.1161/01.CIR.104.2.203

van der Vorst, 2015, Chemokines and their receptors in Atherosclerosis, J Mol Med (Berl), 93, 963, 10.1007/s00109-015-1317-8

Hyafil, 2017, Imaging the cytokine receptor CXCR4 in atherosclerotic plaques with the radiotracer (68)Ga-pentixafor for PET, J Nucl Med, 58, 499, 10.2967/jnumed.116.179663

Weiberg, 2018, Clinical molecular imaging of chemokine receptor CXCR4 expression in atherosclerotic plaque using (68)Ga-Pentixafor PET: Correlation with cardiovascular risk factors and calcified plaque burden, J Nucl Med, 59, 266, 10.2967/jnumed.117.196485

Paulos, 2004, Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis, Adv Drug Deliv Rev, 56, 1205, 10.1016/j.addr.2004.01.012

van der Heijden, 2009, Folate receptor beta as a potential delivery route for novel folate antagonists to macrophages in the synovial tissue of rheumatoid arthritis patients, Arthritis Rheum, 60, 12, 10.1002/art.24219

Ayala-López, 2010, Imaging of atherosclerosis in apoliprotein e knockout mice: Targeting of a folate-conjugated radiopharmaceutical to activated macrophages, J Nucl Med, 51, 768, 10.2967/jnumed.109.071324

Jager, 2012, Targeted folate receptor β fluorescence imaging as a measure of inflammation to estimate vulnerability within human atherosclerotic carotid plaque, J Nucl Med, 53, 1222, 10.2967/jnumed.111.099671

Jager, 2014, Folate receptor-β imaging using 99mTc-folate to explore distribution of polarized macrophage populations in human atherosclerotic plaque, J Nucl Med, 55, 1945, 10.2967/jnumed.114.143180

Silvola, 2018, Aluminum fluoride-18 labeled folate enables in vivo detection of atherosclerotic plaque inflammation by positron emission tomography, Sci Rep, 8, 9720, 10.1038/s41598-018-27618-4

Annovazzi, 2006, 99mTc-interleukin-2 scintigraphy for the in vivo imaging of vulnerable atherosclerotic plaques, Eur J Nucl Med Mol Imaging, 33, 117, 10.1007/s00259-005-1899-4

Ishino, 2008, Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: Potential agent for imaging of vulnerable plaque, J Nucl Med, 49, 1677, 10.2967/jnumed.107.049536

Nishigori, 2013, Radioiodinated peptide probe for selective detection of oxidized low density lipoprotein in atherosclerotic plaques, Nucl Med Biol, 40, 97, 10.1016/j.nucmedbio.2012.08.002

Derlin, 2011, Feasibility of 11C-acetate PET/CT for imaging of fatty acid synthesis in the atherosclerotic vessel wall, J Nucl Med, 52, 1848, 10.2967/jnumed.111.095869

Krohn, 2008, Molecular imaging of hypoxia, J Nucl Med, 49, 129s, 10.2967/jnumed.107.045914

Mateo, 2014, Noninvasive assessment of hypoxia in rabbit advanced atherosclerosis using ¹⁸F-fluoromisonidazole positron emission tomographic imaging, Circ Cardiovasc Imaging, 7, 312, 10.1161/CIRCIMAGING.113.001084

Joshi, 2017, Vascular imaging with (18)F-fluorodeoxyglucose positron emission tomography is influenced by hypoxia, J Am Coll Cardiol, 69, 1873, 10.1016/j.jacc.2017.01.050

Walsh, 2010, Applications of click chemistry in radiopharmaceutical development, Chimia (Aarau), 64, 29, 10.2533/chimia.2010.29

van der Valk, 2015, In vivo imaging of hypoxia in atherosclerotic plaques in humans, JACC Cardiovasc Imaging, 8, 1340, 10.1016/j.jcmg.2014.12.015

Golestani, 2013, Feasibility of vascular endothelial growth factor imaging in human atherosclerotic plaque using (89)Zr-bevacizumab positron emission tomography, Mol Imaging, 12, 235, 10.2310/7290.2012.00034

Hoshiga, 1995, Alpha-v beta-3 integrin expression in normal and atherosclerotic artery, Circ Res, 77, 1129, 10.1161/01.RES.77.6.1129

Laitinen, 2009, Evaluation of alphavbeta3 integrin-targeted positron emission tomography tracer 18F-galacto-RGD for imaging of vascular inflammation in atherosclerotic mice, Circ Cardiovasc Imaging, 2, 331, 10.1161/CIRCIMAGING.108.846865

Johanna, 2009, 68Ga-DOTA-RGD peptide: Biodistribution and binding into atherosclerotic plaques in mice, Eur J Nucl Med Mol Imaging, 36, 2058, 10.1007/s00259-009-1220-z

Kenny, 2008, Phase I trial of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients, J Nucl Med, 49, 879, 10.2967/jnumed.107.049452

Jenkins, 2019, In vivo alpha-V beta-3 integrin expression in human aortic atherosclerosis, Heart, 105, 1868, 10.1136/heartjnl-2019-315103

Heeschen, 2001, Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis, Nat Med, 7, 833, 10.1038/89961

Heeschen, 2002, A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors, J Clin Invest, 110, 527, 10.1172/JCI0214676

Parks, 2004, Matrix metalloproteinases as modulators of inflammation and innate immunity, Nat Rev Immunol, 4, 617, 10.1038/nri1418

Schäfers, 2004, Scintigraphic imaging of matrix metalloproteinase activity in the arterial wall in vivo, Circulation, 109, 2554, 10.1161/01.CIR.0000129088.49276.83

Zhang, 2008, Molecular imaging of activated matrix metalloproteinases in vascular remodeling, Circulation, 118, 1953, 10.1161/CIRCULATIONAHA.108.789743

Kuge, 2010, Imaging with radiolabelled anti-membrane type 1 matrix metalloproteinase (MT1-MMP) antibody: Potentials for characterizing atherosclerotic plaques, Eur J Nucl Med Mol Imaging, 37, 2093, 10.1007/s00259-010-1521-2

Brokopp, 2011, Fibroblast activation protein is induced by inflammation and degrades type I collagen in thin-cap fibroatheromata, Eur Heart J, 32, 2713, 10.1093/eurheartj/ehq519

Stein, 2021, Deletion of fibroblast activation protein provides atheroprotection, Cardiovasc Res, 117, 1060, 10.1093/cvr/cvaa142

Altmann, 2021, The latest developments in imaging of fibroblast activation protein, J Nucl Med, 62, 160, 10.2967/jnumed.120.244806

Wu, 2022, Feasibility of in vivo imaging of fibroblast activation protein in human arterial walls, J Nucl Med, 63, 948, 10.2967/jnumed.121.262863

Manca, 2001, 111In platelet scintigraphy for the noninvasive detection of carotid plaque thrombosis, Stroke, 32, 719, 10.1161/01.STR.32.3.719

Temma, 2010, Tissue factor detection for selectively discriminating unstable plaques in an atherosclerotic rabbit model, J Nucl Med, 51, 1979, 10.2967/jnumed.110.081216

Lohrke, 2017, (18)F-GP1, a Novel PET tracer designed for high-sensitivity, low-background detection of thrombi, J Nucl Med, 58, 1094, 10.2967/jnumed.116.188896

Morris, 2011, Detection of pulmonary emboli with 99mTc-labeled anti-D-dimer (DI-80B3)Fab' fragments (ThromboView), Am J Respir Crit Care Med, 184, 708, 10.1164/rccm.201104-0624OC

Blasi, 2015, Radiation dosimetry of the fibrin-binding probe ⁶⁴Cu-FBP8 and its feasibility for pet imaging of deep vein thrombosis and pulmonary embolism in rats, J Nucl Med, 56, 1088, 10.2967/jnumed.115.157982

Chae, 2019, A phase 1, first-in-human study of (18)F-GP1 positron emission tomography for imaging acute arterial thrombosis, EJNMMI Res, 9, 3, 10.1186/s13550-018-0471-8

de Jong, 1997, Oxidative damage does not alter membrane phospholipid asymmetry in human erythrocytes, Biochemistry, 36, 6768, 10.1021/bi962973a

Kagan, 2000, Oxidative signaling pathway for externalization of plasma membrane phosphatidylserine during apoptosis, FEBS Lett, 477, 1, 10.1016/S0014-5793(00)01707-5

Yang, 1997, Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked, Science, 275, 1129, 10.1126/science.275.5303.1129

Reed, 1997, Cytochrome c: Can't live with it–can't live without it, Cell, 91, 559, 10.1016/S0092-8674(00)80442-0

Kietselaer, 2004, Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis, N Engl J Med, 350, 1472, 10.1056/NEJM200404013501425

Hu, 2018, A comparison of [(99m)Tc]Duramycin and [(99m)Tc]Annexin V in SPECT/CT imaging atherosclerotic plaques, Mol Imaging Biol, 20, 249, 10.1007/s11307-017-1111-9

Chaudhry, 2020, Molecular imaging of apoptosis in atherosclerosis by targeting cell membrane phospholipid asymmetry, J Am Coll Cardiol, 76, 1862, 10.1016/j.jacc.2020.08.047

Cohen, 2009, From the Gla domain to a novel small-molecule detector of apoptosis, Cell Res, 19, 625, 10.1038/cr.2009.17

Hyafil, 2015, Detection of apoptotic cells in a rabbit model with atherosclerosis-like lesions using the positron emission tomography radiotracer [18F]ML-10, Mol Imaging, 14, 433, 10.2310/7290.2015.00017

Jinzaki, 2012, Detection of attenuated plaque in stable angina with 64-multidetector computed tomography: A comparison with intravascular ultrasound, Circ J, 76, 1182, 10.1253/circj.CJ-11-1078

Derlin, 2010, Feasibility of 18F-sodium fluoride PET/CT for imaging of atherosclerotic plaque, J Nucl Med, 51, 862, 10.2967/jnumed.110.076471

Fiz, 2015, ¹⁸F-NaF uptake by atherosclerotic plaque on PET/CT imaging: Inverse correlation between calcification density and mineral metabolic activity, J Nucl Med, 56, 1019, 10.2967/jnumed.115.154229

Irkle, 2015, Identifying active vascular microcalcification by (18)F-sodium fluoride positron emission tomography, Nat Commun, 6, 7495, 10.1038/ncomms8495

Gössl, 2010, Segmental heterogeneity of vasa vasorum neovascularization in human coronary atherosclerosis, JACC Cardiovasc Imaging, 3, 32, 10.1016/j.jcmg.2009.10.009

Derlin, 2011, Correlation of inflammation assessed by 18F-FDG PET, active mineral deposition assessed by 18F-fluoride PET, and vascular calcification in atherosclerotic plaque: A dual-tracer PET/CT study, J Nucl Med, 52, 1020, 10.2967/jnumed.111.087452

Dweck, 2012, Coronary arterial 18F-sodium fluoride uptake: A novel marker of plaque biology, J Am Coll Cardiol, 59, 1539, 10.1016/j.jacc.2011.12.037

Kwiecinski, 2020, Coronary (18)F-sodium fluoride uptake predicts outcomes in patients with coronary artery disease, J Am Coll Cardiol, 75, 3061, 10.1016/j.jacc.2020.04.046

Kavanagh, 2006, The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs, Proc Natl Acad Sci U S A, 103, 7829, 10.1073/pnas.0601643103

Zimmermann, 2021, Stenting "Vulnerable" but fractional flow reserve-negative lesions: Potential statistical limitations of ongoing and future trials, JACC Cardiovasc Interv, 14, 461, 10.1016/j.jcin.2020.05.036

Prati, 2021, Potential of an approach based on the identification and treatment of vulnerable coronary plaques, JACC Cardiovasc Interv, 14, 468, 10.1016/j.jcin.2020.12.033

Piepoli, 2016, Eur Heart J, 37, 2315, 10.1093/eurheartj/ehw106

Arnett, 2019, 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines, J Am Coll Cardiol, 74, 1376, 10.1016/j.jacc.2019.03.009

Yamagishi, 2021, JCS 2018 guideline on diagnosis of chronic coronary heart diseases, Circ J, 85, 402, 10.1253/circj.CJ-19-1131

Navarese, 2018, Association between Baseline LDL-C Level and total and cardiovascular mortality after LDL-C lowering: A systematic review and meta-analysis, Jama, 319, 1566, 10.1001/jama.2018.2525

Schwartz, 2018, Alirocumab and cardiovascular outcomes after acute coronary syndrome, N Engl J Med, 379, 2097, 10.1056/NEJMoa1801174

Ridker, 2017, Antiinflammatory therapy with canakinumab for atherosclerotic disease, N Engl J Med, 377, 1119, 10.1056/NEJMoa1707914

Ridker, 2019, Low-dose methotrexate for the prevention of atherosclerotic events, N Engl J Med, 380, 752, 10.1056/NEJMoa1809798

Zheng, 2018, Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: A systematic review and meta-analysis, Jama, 319, 1580, 10.1001/jama.2018.3024

Shin, 2022, Cardiovascular outcomes in patients initiating first-line treatment of Type 2 diabetes with sodium-glucose cotransporter-2 inhibitors versus metformin: A cohort study, Ann Intern Med, 175, 927, 10.7326/M21-4012

Day, 2020, The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice, Biochem J, 477, 2347, 10.1042/BCJ20200278

Chen, 2022, Sodium-Glucose Co-Transporter 2 (SGLT2) inhibitor dapagliflozin stabilizes diabetes-induced atherosclerotic plaque instability, J Am Heart Assoc, 11, 10.1161/JAHA.121.022761